Table 2.

Inhibition of CCR5-tropic HIV-1 infection by lentiviral vector-mediated delivery of anti-CCR5 siRNA in human PBLs

Donor	Treatment*	Response to CCR5-tropic HIV-1 challenge			Response to CXCR4-tropic HIV-1 challenge
		% of HSA+ cells in the GFP− population†	% of HSA+ cells in the GFP+ population†	Fold of inhibition‡	% of HSA+ cells in the GFP− population†	% of HSA+ cells in the GFP+ population†	Fold of inhibition‡
A	Mock	4.07	N/A		4.82	N/A
	FG12	4.26	5.64		7.26	8.70
	lacZ-siRNA	4.16	5.39		7.94	8.33
	CCR5-siRNA	2.02	1.48	3.64	5.90	5.76	1.45
B	Mock	5.05	N/A		6.07	N/A
	FG12	7.16	7.95		5.15	5.78
	lacZ-siRNA	7.98	11.08		7.76	8.15
	CCR5-siRNA	2.55	1.73	6.41	6.91	7.41	1.10

N/A, not applicable. 

^*The lentivector-transduced PBLs were challenged with the CCR5- or CXCR4-tropic reporter HIV-1 viruses as described in Fig. 3. Four days after virus challenge, the cells were analyzed by FACS for HSA expression to determine the number of cells infected by the HIV-1 virus (Materials and Methods). 

^† Calculated from the quadrant percentage numbers from the HSA vs. GFP FACS plots shown in Fig. 3. 

^‡ Expressed as the ratio of the percentage of HSA+ cells in the GFP+ population between lacZ-siRNA and CCR5-siRNA [CCR5-siRNA(186)]-transduced samples.